



Food and Agriculture
Organization of the
United Nations



World Organisation
for Animal Health

Updates from the 6th PPR Vaccine Producers Meeting

Dr Duriya Charypkhan

PPR Secretariat



GF-TADs

GLOBAL FRAMEWORK FOR THE
PROGRESSIVE CONTROL OF
TRANSBOUNDARY ANIMAL DISEASES



Food and Agriculture
Organization of the
United Nations




World Organisation
for Animal Health

The sixth PPR vaccine producers meeting





Context and Purpose




Previous meetings in Nepal (2014), Morocco (2017), Jordan (2019), virtually (2021), and India (2023)

- Supported by Dollvet, brought together producers from Africa, the Middle East, Asia, and Europe
- Reviewed progress since 2023 meeting in India
- Discussed vaccine quality, production capacity, thermotolerant and DIVA vaccines





Main discussion points

- 
- Some government producers are seeking help in securing vaccine seeds from reference labs
 - Requesting also DIVA strains
 - Support in QC needed
 - Production capacity exceeds the current demands



Research and Innovation

- 
- 
- Rapid advances in thermotolerant and DIVA vaccine R&D
 - MCI: Developing combined and DIVA vaccines
 - JOVAC: Up-scaling Nig 75/1 DIVA strain – safe at 10× dose
 - Promote technology transfer and knowledge sharing within GREN





Why DIVA

- Conventional vaccines limit sero-surveillance differentiation
- Enable safe trade and regional control
- Align with WOAAH Resolution No. 29 promoting new vaccine platforms



Global momentum

- 
- 
- WOAHA developing Target Product Profiles (TPPs) for priority diseases
 - Promotes new biotech platforms (mRNA, viral vectors)
 - Ensures trade recognition of vaccinated animals
 - Supports consensus inclusion of DIVA vaccines in standards

Urgency and Market Opportunity

PPR incursions toward Europe heighten urgency


DIVA vaccines enable:



- Pre-emptive vaccination in at-risk zones
- “Free with vaccination” status (FMD-like model)
- Safe trade and new markets
- Growth in diagnostics and high-value vaccines



Main recommendations



- 
- Finalize PPR DIVA **Target Product Profile (TPP)**
 - Integrate DIVA vaccines & diagnostics into WOAHP Manual & Code
 - Conduct national risk analyses for DIVA/TT use
 - Strengthen public–private partnerships
 - Mobilize funding for R&D and field testing

- 
- 
- 7th PPR Vaccine Producers Meeting: **April 2027, Morocco (Biopharma)**
 - Producers to report DIVA/TT vaccine progress
 - Continued coordination with FAO-WOAH Secretariat and AU-PANVAC